Buy new:
-21% $30.89
FREE delivery Saturday, May 11 on orders shipped by Amazon over $35
Ships from: Amazon.com
Sold by: Amazon.com
$30.89 with 21 percent savings
List Price: $38.99

The List Price is the suggested retail price of a new product as provided by a manufacturer, supplier, or seller. Except for books, Amazon will display a List Price if the product was purchased by customers on Amazon or offered by other retailers at or above the List Price in at least the past 90 days. List prices may not necessarily reflect the product's prevailing market price.
Learn more
Get Fast, Free Shipping with Amazon Prime FREE Returns
FREE delivery Saturday, May 11 on orders shipped by Amazon over $35
Or fastest delivery Friday, May 10. Order within 3 hrs 15 mins
In Stock
$$30.89 () Includes selected options. Includes initial monthly payment and selected options. Details
Price
Subtotal
$$30.89
Subtotal
Initial payment breakdown
Shipping cost, delivery date, and order total (including tax) shown at checkout.
Ships from
Amazon.com
Ships from
Amazon.com
Sold by
Amazon.com
Sold by
Amazon.com
Returns
Eligible for Return, Refund or Replacement within 30 days of receipt
Eligible for Return, Refund or Replacement within 30 days of receipt
This item can be returned in its original condition for a full refund or replacement within 30 days of receipt.
Read full return policy
Returns
Eligible for Return, Refund or Replacement within 30 days of receipt
This item can be returned in its original condition for a full refund or replacement within 30 days of receipt.
Read full return policy
Payment
Secure transaction
Your transaction is secure
We work hard to protect your security and privacy. Our payment security system encrypts your information during transmission. We don’t share your credit card details with third-party sellers, and we don’t sell your information to others. Learn more
Payment
Secure transaction
We work hard to protect your security and privacy. Our payment security system encrypts your information during transmission. We don’t share your credit card details with third-party sellers, and we don’t sell your information to others. Learn more
$28.12
Get Fast, Free Shipping with Amazon Prime FREE Returns
Little to no damage on cover or pages. Packaging shows minimal signs of wear, consistent with being opened. Little to no damage on cover or pages. Packaging shows minimal signs of wear, consistent with being opened. See less
FREE delivery Saturday, May 11 on orders shipped by Amazon over $35. Order within 3 hrs 15 mins
Only 1 left in stock - order soon.
$$30.89 () Includes selected options. Includes initial monthly payment and selected options. Details
Price
Subtotal
$$30.89
Subtotal
Initial payment breakdown
Shipping cost, delivery date, and order total (including tax) shown at checkout.
Access codes and supplements are not guaranteed with used items.
Amazon book clubs early access
Loading your book clubs
There was a problem loading your book clubs. Please try again.
Not in a club? Learn more
Amazon book clubs early access

Join or create book clubs

Choose books together

Track your books
Bring your club to Amazon Book Clubs, start a new book club and invite your friends to join, or find a club that’s right for you for free.
Explore Amazon Book Clubs
Kindle app logo image

Download the free Kindle app and start reading Kindle books instantly on your smartphone, tablet, or computer - no Kindle device required.

Read instantly on your browser with Kindle for Web.

Using your mobile phone camera - scan the code below and download the Kindle app.

QR code to download the Kindle App

Follow the author

Donald L. Drakeman
Follow
Something went wrong. Please try your request again later.

From Breakthrough to Blockbuster: The Business of Biotechnology

4.6 4.6 out of 5 stars 11 ratings
See all formats and editions
{"desktop_buybox_group_1":[{"displayPrice":"$30.89","priceAmount":30.89,"currencySymbol":"$","integerValue":"30","decimalSeparator":".","fractionalValue":"89","symbolPosition":"left","hasSpace":false,"showFractionalPartIfEmpty":true,"offerListingId":"gub6O0Y%2FzQ4VkdbzfWzVGWauO1A%2BXYuKfpW59BSLeWcLtkXnylfftymI5sQ8DPKrrywqgaP3GpO%2BpauDTtDG8rWTcLdbZtwjrmlWWk7b%2Fu4uqxwqNpjpTREOVLxegKZdxHc3YdyXVcGdhvOkJvtiuQ%3D%3D","locale":"en-US","buyingOptionType":"NEW","aapiBuyingOptionIndex":0}, {"displayPrice":"$28.12","priceAmount":28.12,"currencySymbol":"$","integerValue":"28","decimalSeparator":".","fractionalValue":"12","symbolPosition":"left","hasSpace":false,"showFractionalPartIfEmpty":true,"offerListingId":"gub6O0Y%2FzQ4VkdbzfWzVGWauO1A%2BXYuKPRmQwqkS1Vs8oDgLwzIdPyvUAM%2Fc7M5w7NasXvN0ucy3S1YFGgNAVcupsad171Yf1IVv%2BAx90QHhnQcQAbn0DyAv%2BgMCcoRpwC02WbQETKUJ9pSHUxP2sVgkB6hSi6XW801hIv5O1c8jBKydJe8y3TQk9DFmgxy9","locale":"en-US","buyingOptionType":"USED","aapiBuyingOptionIndex":1}]}

Purchase options and add-ons

Financial Times Business Top Title March 2022

How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma, one of the world's most breathtakingly expensive and highly regulated industries?

Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources.

Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs.

From Breakthrough to Blockbuster: The Business of Biotechnology focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions.
Previous page
  1. ISBN-10
    0195084004
  2. ISBN-13
    978-0195084009
  3. Publisher
    Oxford University Press
  4. Publication date
    April 29, 2022
  5. Language
    English
  6. Dimensions
    9 x 1 x 6 inches
  7. Print length
    240 pages
  8. See all details
Next page
Books with Buzz
Books with Buzz
Discover the latest buzz-worthy books, from mysteries and romance to humor and nonfiction. Explore more

Frequently bought together

From Breakthrough to Blockbuster: The Business of Biotechnology
$30.89
Get it as soon as Saturday, May 11
In Stock
Ships from and sold by Amazon.com.
+
Building Backwards to Biotech: The Power of Entrepreneurship to Drive Cutting-Edge Science to Market
$18.62
Get it as soon as Saturday, May 11
In Stock
Ships from and sold by Amazon.com.
+
For Blood and Money: Billionaires, Biotech, and the Quest for a Blockbuster Drug
$15.56
Get it as soon as Saturday, May 11
In Stock
Ships from and sold by Amazon.com.
Total price:
To see our price, add these items to your cart.
Details
Added to Cart
Choose items to buy together.

Editorial Reviews

Review

"Written with authority" -- Financial Times

"A fascinating guide to the complex business of biotechnology, with deep insights into the key factors, players, interactions and behaviors that have shaped the success of this industry. Suitable as a primer for those with no knowledge of the field, or as a refresher for the cognoscenti. Trigger warning: contains material that may distress pharma management" -- Sir Gregory Winter FRS, Trinity College, Cambridge University, recipient of 2018 Nobel Prize in Chemistry

"A must read for all biotechnology leaders, this is a state-of-the-art analysis of the industry from two of its most successful entrepreneurs and a top business school professor, bringing rigor and actionable insight." -- Dr Richard Mason, CEO of Apollo Therapeutics and former head of Johnson & Johnson's London Innovation Center

"How is it possible that a few thousand small companies, many of them short-lived, can out-compete the mighty pharma majors at their own game? Understanding this puzzle is of fundamental importance for industry leaders and policy makers alike. This marvelous insider analysis is a must-read." -- Stefan Scholtes, Dennis Gillings Professor of Health Management, Cambridge University Centre for Health Leadership & Enterprise

"A remarkable synthesis and analysis of the Biotech industry that is a must-read for those trying to develop new life-saving medicines." -- Margaret A. Liu, M.D., DSchc, MDhc, FISV, CEO of Pax Therapeutics, and board member, Ipsen, S.A.

"Anyone who wants to understand how to leverage ecosystems for innovation in the face of uncertainty must read this rigorous analysis of how biotech companies, investors, government and big pharma have worked together to achieve some of the biggest scientific and commercial breakthroughs of the last century." -- Arnoud De Meyer, Professor Emeritus and former President, Singapore Management University

"A must read for everybody interested in the medical biotech industry, practically relevant and theoretically sound." -- Jürgen Mihm, , Professor of Technology and Operations Management at INSEAD

"An outstanding overview of the science and the business of innovative drugs. Students, researchers and policy makers will be immensely benefited from this book." -- Mahmud Hassan, Ph.D, Professor and Director, Pharmaceutical Management Program, Rutgers Business School

About the Author

Donald Drakeman, PhD, was the founding CEO of the US biotech company that pioneered the development of the checkpoint inhibitor cancer treatments recognized in the Nobel Prize for Medicine 2018. These products, YERVOY and OPDIVO, are being used to treat many different forms of cancer. He is a Fellow in Operations and Technology Management at the Cambridge Judge Business School, Distinguished Research Professor in the Program on Constitutional Studies at the University of Notre Dame, and a Venture Partner at Advent Life Sciences. His publications have been cited in numerous patents and by the Supreme Court of the United States. He is a Fellow of the Royal Society of Biology. A graduate of Columbia Law School, he received a PhD from Princeton University.

Lisa Drakeman, PhD, was the founding CEO of one of Europe's most successful biotechnology companies. Under her leadership, the company set numerous financing records, including a record setting IPO, and inaugurated research programs leading to the new FDA-approved medicines DARZALEX (multiple myeloma) and KESIMPTA (multiple sclerosis). She is a member of the board of the Medical University of South Carolina Foundation for Research Development. She has received numerous industry honors, including the Sol J. Barer Award for Vision, Innovation, and Leadership. She has been a faculty member at Princeton University and regularly lectures on entrepreneurship at universities in the US and Europe. She received a PhD from Princeton University.

Nektarios Oraiopoulos, PhD, is the Director of the MPhil Programme in Strategy, Marketing, & Operations and an Associate Professor of Operations and Technology Management at the Cambridge Judge Business School of the University of Cambridge. His research on innovation and R&D management has appeared in the leading journals of the field. He has won multiple awards and has been invited to make presentations at both academic and industry conferences. In addition to his academic work, he has advised entrepreneurial start-ups and has worked closely on research projects with numerous executives from the biopharmaceutical industry. He holds a Diploma in Electrical and Computer Engineering from the National Technical University of Athens and a PhD in Business Administration from the Georgia Institute of Technology.

Product details

  • Publisher ‏ : ‎ Oxford University Press (April 29, 2022)
  • Language ‏ : ‎ English
  • Hardcover ‏ : ‎ 240 pages
  • ISBN-10 ‏ : ‎ 0195084004
  • ISBN-13 ‏ : ‎ 978-0195084009
  • Item Weight ‏ : ‎ 1.01 pounds
  • Dimensions ‏ : ‎ 9 x 1 x 6 inches
  • Customer Reviews:
    4.6 4.6 out of 5 stars 11 ratings

About the author

Follow authors to get new release updates, plus improved recommendations.
Donald L. Drakeman

Donald L. Drakeman

Brief content visible, double tap to read full content.
Full content visible, double tap to read brief content.

Discover more of the author’s books, see similar authors, read author blogs and more

Customer reviews

4.6 out of 5 stars
4.6 out of 5
11 global ratings

Top reviews from the United States

Michael
5.0 out of 5 stars Outstanding! Well written, outstanding exhibits which are easy to read on kindle.
Reviewed in the United States on September 24, 2023
Verified Purchase
I teach a synchronous remote zoom course on the business of biotech at UC San Diego. This book is an outstanding read about most aspects of the subject. I’m recommending it to all my students. My course is a workshop that delves into the details of each topic through business school cases, exercises, mock negotiations and lively interactive discussions. The broad biotech background contained in this book is excellent supporting material for my course.
Helpful
 Report
scott
5.0 out of 5 stars Fascinating and Easy To Read
Reviewed in the United States on July 10, 2022
Verified Purchase
This topic is worth learning more about - for anyone in any business, and anyone who uses prescription drugs - which is almost all of us.
This book is written in a conversational style which makes it an easy read for an ordinary person - no expertise required. A great read!
Helpful
 Report